Brigatinib (BRG) in anaplastic lymphoma kinase (ALK)-positive nonsmall cell lung cancer (NSCLC): Long-term efficacy and safety results from a phase 1/2 trial

Authors
Category Primary study
JournalAnnals of Oncology
Year 2017
This article has no abstract
Epistemonikos ID: 01c684970fcf9e7dad126b113d5cfc56e933e5f2
First added on: Dec 20, 2022